Boston Scientific targets key market

Article Excerpt

BOSTON SCIENTIFIC CORP., $38.88, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (www.bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $55.1 billion; No dividends paid) is now buying the global surgical business of Lumenis Ltd. for $1.07 billion in cash from Baring Private Equity Asia. Lumenis’ surgical business includes laser systems, fibres and accessories used for urology and otolaryngology (head and neck) procedures. Boston Scientific expects the Lumenis acquisition to expand its global footprint throughout Europe and Asia and to accelerate the delivery of its already-strong kidney and urinary stone product lines worldwide. Boston Scientific is a buy. buy…